首頁 › 頭頸部鱗狀細胞癌 › 威斯康辛州 › Milwaukee
Milwaukee, WI 的 頭頸部鱗狀細胞癌 臨床試驗
13 項針對 頭頸部鱗狀細胞癌 的研究正在 Milwaukee（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
招募中3 期
- Aurora Cancer Care-Milwaukee, Milwaukee
- Aurora Saint Luke's Medical Center, Milwaukee
- Medical College of Wisconsin, Milwaukee
- 還有 8 項
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
招募中2/3 期
- Site # 0153, Milwaukee
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
招募中1 期
- Exelixis Clinical Site #33, Milwaukee
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
招募中3 期
- Aurora Cancer Care-Milwaukee, Milwaukee
- Aurora Saint Luke's Medical Center, Milwaukee
- Aurora Sinai Medical Center, Milwaukee
- 還有 8 項
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
招募中1 期
- Research Site, Milwaukee
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
招募中2 期
- Medical College of Wisconsin, Milwaukee
- ProHealth Waukesha Memorial Hospital, Waukesha · 距離 17 英里
- UW Cancer Center at ProHealth Care, Waukesha · 距離 17 英里
- 還有 1 項
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
招募中2 期
- Medical College of Wisconsin, Milwaukee
- Drexel Town Square Health Center, Oak Creek · 距離 11 英里
- Froedtert Menomonee Falls Hospital, Menomonee Falls · 距離 14 英里
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
招募中1/2 期
- Froedtert & MCW Cancer Center, Milwaukee
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
招募中2 期
- Aurora Cancer Care-Milwaukee, Milwaukee
- Aurora Saint Luke's Medical Center, Milwaukee
- Aurora Sinai Medical Center, Milwaukee
- 還有 5 項
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
招募中2/3 期
- Medical College of Wisconsin, Milwaukee
- Drexel Town Square Health Center, Oak Creek · 距離 11 英里
- Froedtert and MCW Moorland Reserve Health Center, New Berlin · 距離 11 英里
- 還有 1 項
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
招募中2 期
- Medical College of Wisconsin, Milwaukee
- Zablocki Veterans Administration Medical Center, Milwaukee
- Drexel Town Square Health Center, Oak Creek · 距離 11 英里
- 還有 1 項
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
招募中3 期
- Medical College of Wisconsin, Milwaukee
- Drexel Town Square Health Center, Oak Creek · 距離 11 英里
- Froedtert and MCW Moorland Reserve Health Center, New Berlin · 距離 11 英里
- 還有 1 項
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
招募中1/2 期
- Froedtert & the Medical College of Wisconsin, Milwaukee
其他城市的 頭頸部鱗狀細胞癌 試驗
- Houston, TX47 項研究
- Los Angeles, CA42 項研究
- Boston, MA40 項研究
- Nashville, TN39 項研究
- New York City, NY39 項研究
- St. Louis, MO28 項研究
- Arlington, VA26 項研究
- Chicago, IL26 項研究
- Philadelphia, PA26 項研究
- Atlanta, GA24 項研究
- San Antonio, TX22 項研究
- Pittsburgh, PA22 項研究
Milwaukee 的其他研究
- 乳癌23 項研究
- 癌症（所有類型）22 項研究
- 非小細胞肺癌22 項研究
- 多發性骨髓瘤21 項研究
- 肺癌21 項研究
- 前列腺癌20 項研究
- 濾泡性淋巴瘤19 項研究
- 非霍奇金淋巴瘤18 項研究
- 胰臟癌18 項研究
- 急性髓系白血病17 項研究
- 卵巢癌17 項研究
- 瀰漫性大B細胞淋巴瘤16 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。